SeaBeLife is a French preclinical stage biotech company set up in 2019 by Morgane Rousselot, PhD., CEO and 3 scientits inventors of the technology. We develop a new disruptive therapeutic approach expected to halve the medical burden including the death rate of severe pathologies without effective treatment. For that, we develope First-In-Class Drugs based on a plateform technology: small molecules which stop the death of the cells and can prevent full organ failure. We have a pipeline of 100 active molecules protected by patents exclusively licensed to SeaBeLife. Two assets are under preclinical development:
- SBL01 to treat the rare but severe life-threatening Acute Liver Injuries (ALI) diseases that represent a social and economic burden due to prolonged hospitalization, mostly in intensive care units, accompanied by multiple complications that often lead to critical organ failure. ALIs are fatal in 30% of cases, despite the progress in intensive care and liver transplantation.
-SBL02 to prevent the loss of vision of patients with Dry-AMD, the first cause of blindness in the over 50 years old affecting more than 5 million patient worldwide each year. Patient mobility is severely impacted, resulting in a loss of independence and Vision loss can lead to reduced quality of life in patients.
SeaBeLife is looking for 2M€ investment to bring its 2 lead compounds to the clinic and sign off its first deal with pharmaceutical company.